Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 39NIH 6NETWORK 3OTHER_GOV 2INDUSTRY 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 27Leukemia 16Lung Neoplasms 13Neuroblastoma 12Burkitt Lymphoma 11Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Sarcoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Central Nervous System Neoplasms 9Brain Neoplasms 9Teratoma 8Carcinoma, Non-Small-Cell Lung 7Wilms Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Leukemia, Myeloid, Acute 6Testicular Neoplasms 5Lymphoma, Non-Hodgkin 5Ovarian Neoplasms 4Medulloblastoma 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Endodermal Sinus Tumor 4Dendritic Cell Sarcoma, Interdigitating 4Carcinoma, Embryonal 4Sarcoma, Ewing 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × Etoposide × Clear all
NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT00002657 2013-01-24

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

SWOG Cancer Research Network

Phase 2 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡